Anti-β-Amyloid (22-35) antibody produced in rabbit

affinity isolated antibody, buffered aqueous solution

Anti-A4 Amyloid protein, Anti-APPI, Anti-AD1, Anti-ABETA, Anti-ABPP, Anti-Amyloid β A4 protein, Anti-Amyloid-β protein (ABP)
Pricing and availability is not currently available.

biological source


antibody form

affinity isolated antibody

antibody product type

primary antibodies




buffered aqueous solution

mol wt

antigen ~4 kDa

species reactivity

mouse, human, rat


antibody small pack of 25 μL


indirect ELISA: 0.2-0.4 μg/mL using β-amyloid peptide (22-35)
western blot: 0.25-0.5 μg/mL using β-amyloid peptide (1-40)



UniProt accession no.

shipped in

dry ice

storage temp.


Gene Information

human ... APP(351)
mouse ... App(11820)
rat ... App(54226)

Related Categories

General description

Rabbit anti-β-amyloid (22-35) antibody specifically recognizes β-amyloid (22-35), β-amyloid (25-35), β-amyloid (1-40) and β-amyloid (1-42) and does not react with β-amyloid (32-35) and β-amyloid (35-25) by ELISA. The antibody detects β-amyloid (1-40) by immunoblotting (approx. 4kDa). Staining of the β-amyloid (1-40) band in immunoblotting is specifically inhibited by the immunizing peptide.
Cleavage of the amyloid precursor protein (APP) by γ-secretase produces the small fragment amyloid β (Aβ) peptide. Cleavage of APP occurs mostly at residue 40 but to a lesser extent residue 42. The amyloid β peptide contains a ~100 kDa soluble N-terminal fragment, and intracellular C-terminal fragments (CTFs) bearing the complete Aβ domain.
Proteolytic cleavage of the amyloid precursor protein (APP) produces the small fragment amyloid β peptide. Cleavage of APP occurs mostly at residue 40 but to a lesser extent residue 42. Aggregates of amyloid β peptide are found deposited in the brains of Alzheimer′s patients.


synthetic peptide corresponding to amino acids 22-35 of human β-amyloid (1-40) fragment, conjugated to KLH. This sequence corresponds to amino acids 693-706 of the human amyloid precursor protein APP, and is identical in mouse and rat APP.


Rabbit anti-β-amyloid (22-35) antibody can be used for ELISA at a concentration of 0.2-0.4μg/mL using β-amyloid peptide (22-35). The product can also be used for western blot at 0.25-0.5μg/mL using β-amyloid peptide (1-40).
Anti-β-Amyloid (22-35) antibody produced in rabbit has been used in:
  • western blot
  • dot-blot assay
  • indirect enzyme linked immunosorbent assay (ELISA)

Biochem/physiol Actions

Secreted Aβ lead to synaptic and neuritic compromise and glial activation. Aggregates of amyloid β peptide are found deposited in the brains of Alzheimer′s patients. Aβ(25-35) and Aβ(22-35) fragments are highly toxic segments of β-amyloid peptides that promote inflammatory processes in astrocytes and fibrillary aggregation of Aβ, thus representing a promising therapeutic target for Alzheimer′s.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide and 1% bovine serum albumin.


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Mechanisms of Amyloid-beta Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease
Yoon SS, et al.
Biomolecules & Therapeutics, 20, 245-245 (2012)
Mechanisms of transthyretin inhibition of $\beta$-amyloid aggregation in vitro
Li X, et al.
The Journal of Neuroscience, 33(50), 19423-19433 (2013)
IL-1beta, TNF-alpha and Sambucus nigra Reactive Serum Proteins as Biomarkers of Mild Cognitive Impairment and Alzheimer Disease Progression
Castillo LM< et al.
Advances in Alzheimer's disease, 4(04), 99-99 (2015)
An Overview of APP Processing Enzymes and Products
Chow VW, et al.
Neuromolecular Medicine, 12, 1-1 (2010)
Xinwei Zhang et al.
Cell death discovery, 6(1), 113-113 (2020-12-11)
Progressive iron accumulation in the brain and iron-induced oxidative stress are considered to be one of the initial causes of Alzheimer's disease (AD), and modulation of brain iron level shows promise for its treatment. Hepcidin expressed by astrocytes has been...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.